
Sarepta Defies FDA, Keeps Shipping Gene Therapy
Sarepta Therapeutics refused an FDA request to halt shipments of its gene therapy, Elevidys, following the death of a third patient. The FDA cited safety concerns after the deaths of three patients, all linked to liver injury, but Sarepta maintains that its scientific review shows no new safety...








